DaunoXome
Active Ingredient(s): Daunorubicin LiposomalFDA Approved: * April 8, 1996
Pharm Company: * GILEAD
Category: Cancer
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
DaunoXome Overview
Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer.[2] Specifically it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma.[2] It is used by injection into a vein.[2] A liposomal formulation known as liposomal daunorubicin also exists.[2] Common side effects include hair loss, vomiting, bone marrow suppression, ...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daunorubicin
Recent DaunoXome Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Daunorubicin Liposomal
- Injection: 2mg/ml
- Injection, Liposomal: 2mg/ml
NDC Database Records for DaunoXome: (1 result)
Sorted by National Drug Code- 10885-001 Daunoxome 2 mg/ml Intravenous Injection, Lipid Complex by Galen Us Inc